11-Mar-2020 - G.ST Antivirals GmbH

Sugar as a remedy for the common cold

Start-up developing therapies to combat viral infections

Viral infections are currently more topical than ever. Not only are coronavirus and influenza constantly in the news but it is also the season for colds – and, as we all know, colds are caused by rhinovirus. A Medical University of Vienna start-up, "G.ST Antivirals GmbH" now has viral infections in its sights – particularly the rhinovirus. The scientists there found a way to stop the virus and therefore might have discovered a new therapy for treating colds in the future.

The Achilles heel of viruses

Viruses do not have their own metabolism and are therefore entirely dependent on the host cell to supply the building blocks they need to multiply. Since proliferation of viruses entails an extremely high nutrient intake, viruses have found strategies to force host cells to increase their uptake of nutrients, since an efficient infection cycle is only possible with increased energy turnover.

The researchers at G.ST Antivirals are exploiting this situation to develop treatments that stop the virus from having access to the host cell's metabolic products. The first virus for which the founding team was able to apply this concept is rhinovirus, the pathogen that causes the common cold. In the course of studies conducted at the Medical University of Vienna, they discovered that the virus is particularly vulnerable to inhibition of sugar utilisation.

Sugar as a remedy for the common cold

"Based on these concepts, our team has identified a substance that is highly effective against rhinoviruses, 2-Deoxyglucose. The compound inhibits glycolysis in the host cell, thus starving the virus inside the cell," explain Guido Gualdoni (MedUni Vienna's Department of Medicine III) and Johannes Stöckl (MedUni Vienna's Institute of Immunology). "Since it is cheap to produce and highly effective, the molecule has the ideal pre-requisites for widespread application as a cold remedy."

Since a lot of data is already available regarding the good tolerability of the substance, G.ST Antivirals wants to start clinical testing of the molecule at Vienna General Hospital and/or MedUni Vienna during the course of 2020. The substance could therefore be marketed within what is a very short timeframe for a drug. MedUni Vienna's Technology Transfer Office only filed the patent application for this invention in 2018.

Effective against other viruses as well?

"Since all viruses rely on the metabolism of the host cell, we are currently intensifying our efforts to apply this therapeutic strategy to other viruses as well, such as coronaviruses, for example," say the researchers.

Facts, background information, dossiers
More about G.ST Antivirals
  • News

    New therapeutic approach against rhinovirus infections

    Less than three years after its foundation, the start-up G.ST Antivirals reaches a major milestone in the development of its lead asset and begins clinical phase I at the Vienna General Hospital. G.ST Antivirals is testing a nasal spray, which was developed specifically for use against cold ... more

  • Companies

    G.ST Antivirals GmbH

    G.ST Antivirals is an Austrian start-up founded in 2019 as a spin-off from the Medical University of Vienna. The young company has its roots in extensive research on the inhibition of rhinovirus infections. Based on this, G.ST Antivirals developed a patented, innovative drug against colds. ... more

More about Medizinische Uni Wien
  • News

    New findings on the effects of Covid-19 on the colon

    Although SARS-CoV-2 infections mainly attack the lungs, in many cases they can also damage other organs, such as the colon: around 60% of patients experienced digestive tract impacts. Researchers at MedUni Vienna have analysed the manifestations of Covid-19 in the lungs and colon and pinpoi ... more

    Tick saliva modulates immune system

    Hitherto, scientists have not fully understood why ticks are such dangerous disease vectors. A research team led by Johanna Strobl and Georg Stary from MedUni Vienna's Department of Dermatology shows that tick saliva inhibits the skin's defence function, thereby increasing the risk of disea ... more

    Neuronal back-up system discovered

    Researchers at MedUni Vienna have discovered that neurons have an emergency back-up system to enable them to remain functional even when their energy supply is disrupted. As in many areas of technology, an emergency back-up serves to compensate for any energy supply failures experienced by ... more